Trial record 40 of 57 for:    Friedreich's Ataxia

STEADFAST Long-Term Safety Extension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02797080
Recruitment Status : Completed
First Posted : June 13, 2016
Last Update Posted : April 21, 2017
Friedreich's Ataxia Research Alliance
Information provided by (Responsible Party):
Horizon Pharma Ireland, Ltd., Dublin Ireland

Brief Summary:
The purpose of this long term extension study is to evaluate the long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia (FA).

Condition or disease Intervention/treatment Phase
Friedreich's Ataxia Drug: interferon γ-1b Phase 3

Detailed Description:
This is a multi-center, open-label, long-term safety extension study of ACTIMMUNE® in the treatment of Friedreich's Ataxia (FA) in children and young adults. Participants who complete 26 weeks of treatment and the Week 28 Follow-Up Visit in HZNP-ACT-302 (NCT02593773) will be eligible to enter this long-term safety extension protocol. The Day 1 Visit of this study (HZNP-ACT-303) occurs on the same day as the Week 28 Follow-Up Visit for HZNP-ACT-302 (NCT02593773). Participants will be required to return for clinic visits at least every six months. The treatment duration is open-ended, and treatment will continue until ACTIMMUNE® is commercially available for the treatment of FA in the United States or until the Sponsor decides not to continue development for the treatment of FA.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Study Start Date : June 2016
Actual Primary Completion Date : March 31, 2017
Actual Study Completion Date : March 31, 2017

Arm Intervention/treatment
Experimental: interferon γ-1b Drug: interferon γ-1b
ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m2.
Other Name: ACTIMMUNE®

Primary Outcome Measures :
  1. Number of Participants with Adverse Events [ Time Frame: Baseline up to 2 years ]
    An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered an investigational product, whether or not the event is considered related to the investigational product. An AE is therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the investigational product.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   11 Years to 27 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent and child assent, if applicable.
  • Completed 26 weeks of treatment and the Week 28 Follow-Up visit in Study HZNP-ACT-302 (NCT02593773). .
  • If female, the subject is not pregnant or lactating or intending to become pregnant during the study, or within 30 days after the last dose of study drug. Female subjects of child-bearing potential must have a negative urine pregnancy test result at Week 26 of Study HZNP-ACT-302 (NCT02593773) and agree to use a reliable method of contraception throughout the study and for 30 days after the last dose of study drug.

Exclusion Criteria:

  • If in the opinion of the Investigator, patients have a concomitant disease or condition that could interfere with the conduct of the study or potentially put the subject at unacceptable risk, the subject will be excluded from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02797080

United States, California
University of California, Los Angeles Neurology Clinic
Los Angeles, California, United States, 90038
United States, Florida
University of Florida Clinical Research Center
Gainesville, Florida, United States, 32610
United States, Iowa
University of Iowa Children's Hospital
Iowa City, Iowa, United States, 52242
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Horizon Pharma Ireland, Ltd., Dublin Ireland
Friedreich's Ataxia Research Alliance
Study Director: Julie Ball, MS Horizon Pharma Ireland, Ltd., Dublin Ireland

Responsible Party: Horizon Pharma Ireland, Ltd., Dublin Ireland Identifier: NCT02797080     History of Changes
Other Study ID Numbers: HZNP-ACT-303
First Posted: June 13, 2016    Key Record Dates
Last Update Posted: April 21, 2017
Last Verified: April 2017

Keywords provided by Horizon Pharma Ireland, Ltd., Dublin Ireland:
interferon y-1b

Additional relevant MeSH terms:
Friedreich Ataxia
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinocerebellar Degenerations
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents